mavacamten   Click here for help

GtoPdb Ligand ID: 11265

Synonyms: Camzyos® | MYK-461 | MYK461
Approved drug PDB Ligand
mavacamten is an approved drug (FDA (2022), EMA (2023))
Compound class: Synthetic organic
Comment: Mavacamten (MYK-461) is an orally active myosin allosteric modulator [1] that was developed by MyoKardia as a novel treatment for obstructive hypertrophic cardiomyopathy (HCM). In 2020 MyoKardia was bought by Bristol Myers Squibb. The compound interacts with both α and β cardiac myosins in vitro. Preclinical pharmacokinetics are reported in [2]. Mavacamten attenuates hypertrophic and profibrotic gene expression in rodent models of HCM [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 66.89
Molecular weight 273.15
XLogP 3.79
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H](c1ccccc1)Nc1cc(=O)n(c(=O)[nH]1)C(C)C
Isomeric SMILES C[C@@H](c1ccccc1)Nc1cc(=O)n(c(=O)[nH]1)C(C)C
InChI InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
InChI Key RLCLASQCAPXVLM-NSHDSACASA-N
Download 2D Structure Click here for help
Canonical SMILES Download
Isomeric SMILES Download
InChI standard identifier Download
InChI standard key Download

Molecular structure representations generated using Open Babel